Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare (Solifenacin) From Other Antimuscarinics

Trial Profile

Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare (Solifenacin) From Other Antimuscarinics

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms VEST
  • Sponsors Astellas Pharma BV
  • Most Recent Events

    • 12 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 25 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 29 Oct 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top